Abstract
There is evidence demonstrating that sexual complaints represent the most specific symptoms associated with late onset hypogonadism, while central obesity is the most specific sign. In obese men, hypogonadism can further worsen the metabolic profile and increase abdominal fat. In addition, although hypogonadism can exacerbate obesity-associated erectile dysfunction (ED), recent data suggest that a direct contribution of fat-derived factors could be hypothesized. In particular, an animal model recently documented that fat accumulation induces several hepatic pro-inflammatory genes closely linked to corpora cavernosa endothelial dysfunction. Lifestyle modifications and weight loss are the first steps in the treatment of ED patients with obesity or metabolic diseases. In symptomatic hypogonadal men with metabolic impairment and obesity, combining the effect of testosterone substitution with lifestyle modifications could result in better outcomes.
Article PDF
Similar content being viewed by others
References
Gray A, Feldman HA, McKinlay JB, Longcope C, 1991 Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73: 1016–1025.
Ferrini RL, Barrett-Connor E, 1998 Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 147: 750–754.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging, 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86: 724–731.
Morley JE, Kaiser FE, Perry HM 3rd, et al, 1997 Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46: 410–413.
Wu FC, Tajar A, Pye SR, et al, 2008 Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93: 2737–2745.
Tajar A, Forti G, O’Neill TW, et al, 2010 Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95: 1810–1818.
Buvat J, Maggi M, Guay A, Torres LO, 2013 Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 10: 245–284.
Wang C, Nieschlag E, Swerdloff R, et al, 2009 Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl 32: 1–10.
Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M, 2012 How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14: 251–259.
Corona G, Rastrelli G, Maggi M, 2013 Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 27: 557–579.
Wu FC, Tajar A, Beynon JM, et al, 2010 Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363: 123–135.
Corona G, Mannucci E, Ricca V, et al, 2009 The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 32: 720–728.
Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M, 2011 Hypogonadism and metabolic syndrome. J Endocrinol Invest 34: 557–567.
Kelly DM, Jones TH, 2015 Testosterone and obesity. Obes Rev 16: 581–606.
Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M, 2014 Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl 16: 581–591.
Kaya E, Sikka SC, Gur S, 2015 A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med 12: 856–875.
Vignozzi L, Filippi S, Comeglio P, et al, 2014 Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol Cell Endocrinol 384: 143–154.
Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M, 2015 Obesity and late-onset hypogonadism. Mol Cell Endocrinol doi: 10.1016/j.mce.2015.06.031. [Epub ahead of print]
Corona G, Giorda CB, Cucinotta D, Guida P, Nada E; Gruppo di studio SUBITO-DE, 2014 Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med 11: 2065–2073.
Cheung KK, Luk AO, So WY, et al, 2015 Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig 6: 112–123.
Corona G, Monami M, Rastrelli G, et al, 2011 Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34: 28–40.
Corona G, Monami M, Rastrelli G, et al, 2011 Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8: 72–83.
Brand JS, Rovers MM, Yeap BB, et al, 2014 Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One 9: e100409.
Zumoff B, Strain GW, Miller LK, et al, 1990 Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71: 929–931.
Corona G, Mannucci E, Fisher AD, et al, 2008 Low Levels of Androgens in Men with Erectile Dysfunction and Obesity. J Sex Med 5: 454–463.
Giagulli VA, Kaufman JM, Vermeulen A, 1994 Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 79: 997–1000.
Vermeulen A, Kaufman JM, Deslypere JP, Thomas G, 1993 Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76: 1140–1146.
Costanzo PR, Suárez SM, Scaglia HE, Zylbersztein C, Litwak LE, Knoblovits P, 2014 Evaluation of the hypothalamic-pituitary-gonadal axis in eugonadal men with type 2 diabetes mellitus. Andrology 2: 17–24.
Camacho EM, Huhtaniemi IT, O’Neill TW, et al, 2013 Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 168: 445–455.
Maseroli E, Corona G, Rastrelli G, et al, 2015 Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med 12: 956–965.
Rastrelli G, Carter EL, Ahern T, et al, 2015 Development of and Recovery from Secondary Hypogonadism in Ageing Men: Prospective Results from the EMAS. J Clin Endocrinol Metab 100: 3172–3182.
Morelli A, Comeglio P, Sarchielli E, et al, 2013 Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons. Int J Endocrinol 2013: 684659.
Morelli A, Sarchielli E, Comeglio P, et al, 2014 Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 382: 107–119.
Fernandez-Fernandez R, Martini AC, et al, 2006 Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 254–255: 127–132.
Loves S, de Jong J, van Sorge A, et al, 2013 Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol 169: 705–714.
Corona G, Rastrelli G, Monami M, et al, 2013 Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 168: 829–843.
Dhindsa S, Furlanetto R, Vora M, et al, 2011 Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 34: 1854–1859.
Filippi S, Vignozzi L, Morelli A, et al, 2009 Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 6: 3274–3288.
Herde MK, Geist K, Campbell RA, Herbison AE, 2011 Gonadotropin-releasing hormone neurons extend complex highly branched dendritic trees outside the blood-brain barrier. Endocrinology 152: 3832–3841.
Corona G and Maggi M, 2015 Perspective: regulatory agencies’ changes to testosterone product labelling. J Sex Med 12: 1690–1693.
Singh R, Artaza JN, Taylor WE, et al, 2006 Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147: 141–154.
Gupta V, Bhasin S, Guo W, et al, 2008 Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 296: 32–40.
Maneschi E, Morelli A, Filippi S, et al, 2012 Testosterone treatment improbe metabolic syndrome-induced adipose tissue derangements. J Endocrinol 215: 347–362.
Maneschi E, Vignozzi L, Morelli A, et al, 2013 FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 218: 215–231.
Tuomilehto J, Lindstrom J, Eriksson JG, et al, 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.
Pi-Sunyer X, Blackburn G, Brancati FL, et al, 2007 Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30: 1374–1383.
Nathan DM, Buse JB, Davidson MB, et al, 2009 Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193–203.
Knowler WC, Barrett-Connor E, Fowler SE, et al, 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.
Gillies CL, Abrams KR, Lambert PC, et al, 2007 Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334: 299.
Biswas A, Oh PI, Faulkner GE, et al, 2015 Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 162: 123–132.
Ahtiainen JP, Nyman K, Huhtaniemi I, et al, 2015 Effects of resistance training on testosterone metabolism in younger and older men. Exp Gerontol 69: 148–158.
Maiorino MI, Bellastella G, Esposito K, 2015 Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl 17: 5–10.
Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL, 2011 The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 171: 1797–1803.
Buchwald H, Williams SE, 2004 Bariatric surgery worldwide 2003. Obes Surg 14: 1157–1164.
Vanstone M, Giacomini M, Smith A, Brundisini F, DeJean D, Winsor S, 2013 How diet modification challenges are magnified in vulnerable or marginalized people with diabetes and heart disease: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser 13: 1–40.
Saad F, Haider A, Doros G, Traish A, 2013 Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 21: 1975–1981.
Yassin DJ, Doros G, Hammerer PG, Yassin AA, 2014 Long-Term Testosterone Treatment in Elderly Men with Hypogonadism and Erectile Dysfunction Reduces Obesity Parameters and Improves Metabolic Syndrome and Health-Related Quality of Life. J Sex Med 11: 1567–1576.
Zitzmann M, Saad F, Kliesch S, 2014 Long-term treatment with testosterone undecanoate injections leads to sustained weight loss and improvement of metabolic syndrome parameters in 381 hypogonadal men. J Sex Med 11: Suppl 1: 7.
Corona G, Rastrelli G, Maggi M, 2015 The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother 16: 369–387.
Corona G, Maseroli E, Maggi M, 2014 Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 15: 1903–1926.
Isidori AM, Balercia G, Calogero AE, et al, 2014 Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38: 103–112.
Corona G, Isidori AM, Buvat J, et al, 2014 Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 11: 1577–1592.
Corona G, Giagulli VA, Maseroli E, et al, 2015 Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2015 Nov 4. pii: EJE-15-0262. [Epub ahead of print]
Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A, 2014 Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37: 401–411.
Hildreth KL, Barry DW, Moreau KL, et al, 2013 Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 98: 1891–900.
Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY, 2012 Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 167: 531–541.
Heufelder AE, Saad F, Bunck MC, Gooren L, 2009 Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30: 726–733.
Katznelson L, Robinson MW, Coyle CL, Lee H, Farrell CE, 2006 Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. Eur J Endocrinol 155: 867–875.
Corona G, Fagioli G, Mannucci E, et al, 2008 Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 5: 2623–2634.
Isidori AM, Buvat J, Corona G, et al, 2014 A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol 65: 99–112.
Corona G, Razzoli E, Forti G, Maggi M, 2008 The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 31: 799–808.
Greco EA, Spera G, Aversa A, 2006 Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidence. Eur Urol 50: 940–947.
Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. 2003 Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58: 632–638.
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H, 2004 Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172: 658–663.
Buvat J, Montorsi F, Maggi M, et al, 2011 Hypogonadal men non responders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 8: 284–293.
Spitzer M, Basaria S, Travison TG, et al, 2012 Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 157: 681–691.
Jannini EA, Screponi E, Carosa E, et al, 1999 Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 22: 385–392.
Carosa E, Benvenga S, Trimarchi F, et al, 2002 Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 14: 93–99.
Carosa E, Martini P, Brandetti F, et al, 2004 Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 61: 382–386.
Corona G, Mannucci E, Lotti F, et al, 2009 Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med 6: 2591–2600.
Corona G, Rastrelli G, Monami M, et al, 2013 Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology 1: 864–871.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Corona, G., Bianchini, S., Sforza, A. et al. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones 14, 569–578 (2015). https://doi.org/10.14310/horm.2002.1635
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1635